TOVANOR

This brand name is authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Netherlands, Poland, South Africa, Spain.

Active ingredients

The drug TOVANOR contains one active pharmaceutical ingredient (API):

1	Glycopyrronium UNII H4S7L81L98 - CHLOROGLYCOPYRRONIUM BROMIDE
	Glycopyrronium is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD. Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways.
	Read more about Glycopyrronium

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TOVANOR BREEZHALER Inhalation powder, hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03BB06		R Respiratory system → R03 Drugs for obstructive airway diseases → R03B Other drugs for obstructive airway diseases, inhalants → R03BB Anticholinergics
Discover more medicines within R03BB06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1595819, 1595820, 1595831, 1595842, 1595853, 1595864, 1718478
ES	Centro de información online de medicamentos de la AEMPS	112790003
IT	Agenzia del Farmaco	042313015, 042313027, 042313039, 042313041, 042313054, 042313066, 042313078, 042313080
LT	Valstybinė vaistų kontrolės tarnyba	1067958, 1067959, 1067960, 1067961, 1067962, 1067963, 1080802, 1080803
NL	Z-Index G-Standaard, PRK	103942
PL	Rejestru Produktów Leczniczych	100315344
ZA	Health Products Regulatory Authority	47/10.2.1/0120